British Journal of Cancer

• 

  Publication Venue For

  • Effect of aerobic training on the host systemic milieu in patients with solid tumours: An exploratory correlative study.  112:825-831. 2015
  • Erratum: Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium (British Journal of Cancer (2009) 100 (412-420) DOI: 10.1038/sj.bjc.6604820 www.bjcancer.com).  101:1805. 2009
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs (British Journal of Cancer (2008) 99, (294-304) DOI: 10.1038/sj.bjc.6604459).  100:1012. 2009
  • Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.  100:412-420. 2009
  • Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis..  98:294-299. 2008
  • Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis..  98:282-288. 2008
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts..  97:735-740. 2007
  • Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy..  97:391-397. 2007
  • Regulation of mammalian horizontal gene transfer by apoptotic DNA fragmentation..  95:1696-1700. 2006
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation..  95:1013-1019. 2006
  • HIF-1 and tumour radiosensitivity..  95:1-5. 2006
  • Birth weight and breast cancer risk..  94:1734-1737. 2006
  • Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis..  93:1350-1355. 2005
  • Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York..  93:699-708. 2005
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer..  93:195-199. 2005
  • Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery..  92:1414-1420. 2005
  • Targeted radiotherapy of brain tumours..  90:1469-1473. 2004
  • Invasion and MMP expression profile in desmoid tumours..  90:1443-1449. 2004
  • Surrogate markers in antiangiogenesis clinical trials..  89:8-14. 2003
  • Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk..  88:58-62. 2003
  • Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix..  86:274-281. 2002
  • Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour)..  85:98-101. 2001
  • Transfection of the sodium iodide symporter gene for tumour targeting with radioiodine and [At-211]radioastatine.  85:24-24. 2001
  • Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists..  83:906-913. 2000
  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse..  83:588-593. 2000
  • Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer..  83:324-328. 2000
  • Vascular permeability in a human tumour xenograft: molecular charge dependence..  82:1513-1518. 2000
  • Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features..  82:1191-1197. 2000
  • Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells..  82:691-701. 2000
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522..  81:1274-1279. 1999
  • Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice..  81:966-971. 1999
  • Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow..  80:1927-1934. 1999
  • Bcl10 is not a target for frequent mutation in human carcinomas..  80:1575-1576. 1999
  • G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder..  80:1175-1184. 1999
  • Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia..  79:1717-1722. 1999
  • Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity..  80:87-95. 1999
  • The effects of hyperoxic and hypercarbic gases on tumour blood flow..  80:117-126. 1999
  • Progesterone receptor gene polymorphism and risk for breast and ovarian cancer..  78:277. 1998
  • Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions..  77:2061-2068. 1998
  • Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia..  77:753-759. 1998
  • Combretastatin A-4 P as a tumour vascular targeting agent.  78:48-48. 1998
  • Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis..  77:51-56. 1998
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.  76:226-233. 1997
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells..  76:226-233. 1997
  • Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma..  76:429-437. 1997
  • Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients..  74:1206-1215. 1996
  • Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity..  73:1171-1177. 1996
  • Arteriolar oxygenation in tumour and subcutaneous arterioles: Effects of inspired air oxygen content.  74. 1996
  • Microvascular studies on the origins of perfusion-limited hypoxia.  74. 1996
  • The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation..  72:1120-1124. 1995
  • New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment..  72:250. 1995
  • Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma..  71:1181-1187. 1995
  • Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma..  71:1169-1174. 1995
  • Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma.  71:1169-1174. 1995
  • Differences in leucocyte-endothelium interactions between normal and adenocarcinoma bearing tissues in response to radiation..  69:883-889. 1994
  • The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment..  67:734-741. 1993
  • 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation..  67:209-215. 1993
  • Genetic susceptibility to naevi--a twin study..  64:1164-1167. 1991
  • Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis..  62:637-642. 1990
  • Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer..  62:238-242. 1990
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer..  58:362-367. 1988
  • B-lymphocytes from melanoma patients and normal individuals react with melanoma cells but also with irrelevant antigens..  58:182-185. 1988
  • Influence of tumour size on human prostate tumour metastasis in athymic nude mice..  51:419-423. 1985
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas..  51:283-289. 1985
  • C-type virus particles in human urogenital tumours after heterotransplantation into nude mice..  39:35-42. 1979
  • Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration..  33:634-645. 1976
  • Proceedings: Oral and pharyngeal cancers in textile workers..  32:249. 1975
  • Refusal in testicular cancer patients: implications for surveillance..  65:786. 1992
  • Enhancement of targeted radiotehrapy in neuroblastoma: A novel gene therapy approach 2004
  • Targeted radiotherapy of brain tumours 2003
  • Targets of the ABL tyrosine kinases in normal and transformed cells. 1998